Výsledky vyhledávání

Akademický článek

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Publikováno v: Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)

Abstract Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacit

Externí odkaz: https://doaj.org/article/643e4039c05b4d0693acd3685dcccc4b

Zobrazit plný text záznamu

Akademický článek

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)

Abstract Background Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenet

Externí odkaz: https://doaj.org/article/8383b31ab3964040a696c4af7281e2f3

Zobrazit plný text záznamu

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Autor: Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero

Publikováno v: Blood Advances. 6:2207-2218

Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune checkpoint inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e561d83be82d28260d59fa9ee8ce2c47
https://doi.org/10.1182/bloodadvances.2021005487

Zobrazit plný text záznamu

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Autor: Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueño, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Döhner

Publikováno v: Roboz, G J, Ravandi, F, Wei, A H, Dombret, H, Thol, F, Voso, M T, Schuh, A C, Porkka, K, la Torre, I, Skikne, B, Zhong, J, Beach, C L, Risueño, A, Menezes, D L, Ossenkoppele, G & Döhner, H 2022, ' Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status ', Blood, vol. 139, no. 14, pp. 2145-2155 . https://doi.org/10.1182/blood.2021013404
Blood, 139(14), 2145-2155. American Society of Hematology

Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7365165865d9c4f49870ff6752f37121
https://research.vumc.nl/en/publications/674bc6de-4d6e-4889-948e-24c5998badda

Zobrazit plný text záznamu

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

Autor: Simon Zhou, Yan Li, Kathryn Newhall, Richard Delarue, Stephen E. Maxwell, Vitalina Komashko, Steven Novick, Justine Dell’Aringa, Myron S. Czuczman, Shelonitda Rose, Nurgul Kilavuz, C. L. Beach, Maria Palmisano, Lars Sternas, Ken Ogasawara

Publikováno v: Clinical Pharmacokinetics

Background and Objectives Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5dea39a12f000ad0f40c8032324195
http://europepmc.org/articles/PMC7007418

Zobrazit plný text záznamu

Ractopamine-Induced Changes in the Mitochondrial Proteome of Postmortem Beef Longissimus Lumborum

Autor: C. Zhai, S. P. Suman, S. Li, M. N. Nair, C. M. Beach, B. M. Edenburn, D. D. Boler, A. C. Dilger, T. L. Felix

Publikováno v: Meat and Muscle Biology. 3

ObjectivesRactopamine is a β-adrenergic agonist approved as growth promotant in beef cattle, and it increases muscle deposition while limiting fat deposition. Dietary ractopamine causes a muscle fiber shift in cattle, and the biochemistry of mitocho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5c21d01f54ab795346aefd453925b44
https://doi.org/10.22175/mmb.10708

Zobrazit plný text záznamu

Supranutritional Supplementation of Vitamin E Influences the Abundance of Antioxidant Proteins in Postmortem Longissimus Lumborum from Heifers

Autor: H. M. Kim, S. P. Suman, S. Li, C. M. Beach, C. Zhai, M. N. Nair, B. N. Harsh, D. D. Boler, A. C. Dilger, D. W. Shike

Publikováno v: Meat and Muscle Biology. 3

ObjectivesVitamin E is a lipid-soluble antioxidant that can inhibit lipid oxidation and improve beef color stability. The effect of vitamin E on fresh beef color, from the standpoint of lipid oxidation-induced myoglobin oxidation, have been extensive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0dd383b8f43e46bdf6a7a6fc56470686
https://doi.org/10.22175/mmb.10725

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání